Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | NPBWR1 | P48145 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | GUSB | P08236 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | MMP9 | P14780 | 2/20 | 0.51 |
| ▸ | MMP8 | P22894 | 2/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251968 | 0.90 | NPC1 (0.59) | RAB9AMAPTNPBWR1NPC1SMN1; SMN2 | |
| SCHEMBL988049 | 0.88 | NPC1 (0.60) | RAB9AMAPTNPBWR1NPC1SMN1; SMN2 | |
| SCHEMBL986022 | 0.87 | RAB9A (0.65) | RAB9AMAPTNPBWR1NPC1SMN1; SMN2 | |
| SCHEMBL984215 | 0.86 | MAPT (0.49) | RAB9AMAPTNPBWR1NPC1SMN1; SMN2 | |
| SCHEMBL987534 | 0.86 | NPBWR1 (0.61) | RAB9AMAPTNPBWR1NPC1SMN1; SMN2 | |
| SCHEMBL986061 | 0.86 | MMP13 (0.57) | RAB9AMAPTNPBWR1NPC1SMN1; SMN2 | |
| SCHEMBL987496 | 0.86 | NPBWR1 (0.61) | RAB9AMAPTNPBWR1NPC1SMN1; SMN2 | |
| SCHEMBL984237 | 0.86 | MMP13 (0.57) | RAB9AMAPTNPBWR1NPC1SMN1; SMN2 | |
| SCHEMBL986445 | 0.86 | NPBWR1 (0.63) | RAB9AMAPTNPBWR1NPC1SMN1; SMN2 | |
| SCHEMBL4476782 | 0.85 | RAB9A (0.53) | RAB9AMAPTNPBWR1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024219864-A1 | NOVEL COMPOUND EXHIBITING SETDB1 INHIBITORY ACTIVITY, AND USE THEREOF | 주식회사 넷타겟 | 2024-10-24 | — | — | WO | disclosed |
| EP-2265609-B1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-1919910-B1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2265609-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7786113-B2 | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7776878-B2 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100120840-A1 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-13 | — | — | US | disclosed |
| WO-2009111277-A9 | IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-7618964-B2 | Benzamide derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1919910-A1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | F. Hoffmann-la Roche AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| EP-1912987-A1 | HETEROCYCLIC BENZYLAMINO DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| US-20080039460-A1 | Benzamide Derivatives, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-14 | — | — | US | disclosed |
| US-20080009492-A1 | Heterocyclic Carbamate Derivatives, Their Manufacture And Use As Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-01-10 | — | — | US | disclosed |
| EP-1833829-A2 | BENZAMIDE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| EP-1831218-A2 | CARBAMATE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007017143-A1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007014707-A1 | HETEROCYCLIC BENZYLAMINO DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006066914-A2 | CARBAMATE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006066913-A2 | BENZAMIDE SUBSTITUTED IMIDAZO- AND PYROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | BRAF, RAF1, ARAF | RAB9A 752/4885MAPT 4751/4885NPBWR1 3190/4885 |
| US-20080009492-A1 | Heterocyclic Carbamate Derivatives, Their Manufacture And Use As Pharmaceutical Agents | RCC2, ACMSD, CPS1 | RAB9A 997/4885MAPT 3652/4885NPBWR1 4467/4885 |
| US-20080039460-A1 | Benzamide Derivatives, Their Manufacture and Use as Pharmaceutical Agents | TMBIM6, BAK1, CYP3A5 | RAB9A 1396/4885MAPT 3515/4885NPBWR1 3977/4885 |
| US-20100120840-A1 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | CYP3A5, ABCB1, CYP3A43 | RAB9A 372/4885MAPT 4207/4885NPBWR1 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.